5852-49-3

Usage

Uses

Used in Chemical Synthesis:
5-Phenyl-1,3,4-oxathiazol-2-one is used as a starting material or intermediate in the synthesis of various organic compounds. Its unique structure allows for the formation of derivatives that can be used in the development of new chemical products.
Used in Pharmaceutical Industry:
5-Phenyl-1,3,4-oxathiazol-2-one is used as a potential active pharmaceutical ingredient (API) or as a building block in the design and synthesis of new drugs. Its heterocyclic structure and phenyl group may contribute to the development of novel therapeutic agents with specific pharmacological properties.
Used in Materials Science:
5-Phenyl-1,3,4-oxathiazol-2-one is used as a component in the development of advanced materials, such as polymers, coatings, or composites. Its chemical structure may provide unique properties that can be exploited in the creation of new materials with specific characteristics for various applications.

Upstream product

• 55-21-0 benzamide 
• 594-42-3 chlorothio-trichloro-methane 
• 2757-23-5 chloro(chlorosulfanyl)methanone 
• 28059-36-1 N-benzoyltrichloromethanesulfenamide 
• 1821-34-7 N-chlorobenzamide 
• 7440-44-0 pyrographite 

Downstream Products

• 73501-00-5 5-phenyl-2-trichloromethyl-1,3,4-oxathiazole 
• 50483-74-4 3-phenyl-5-(p-tolyl)-1,2,4-thiadiazole 
• 50483-79-9 ethyl 3-phenyl-1,2,4-thiadiazole-5-carboxylate 
• 67048-45-7 3-phenyl-4,5-dihydro-isothiazole-4r,5t-dicarboxylic acid dimethyl ester 
• 27545-57-9 ethyl 3-phenylisothiazole-5-carboxylate 
• 67049-00-7 ethyl 3-phenyl-1,2-thiazole-4-carboxylate 
• 615-16-7 1,3-dihydro-2H-benzimidazol-2-one 
• 59-49-4 2-Benzoxazolinone 
• 19836-78-3 3-methyl-2-oxo-1,3-oxazolidine 
• 111480-65-0 5-(2-chloro-4,6-dinitrophenylthio)-3-phenyl-1,2,4-thiadiazole 
• 111480-34-3 5-(2,4-dinitrophenylseleno)-3-phenyl-1,2,4-thiadiazole 
• 120587-90-8 3-Phenyl-5-trimethylsilanyl-[1,2,4]thiazaphosphole 
• 109123-14-0 5-tert-Butyl-3-phenyl-1,2,4-thiazaphosphol 
• 120587-93-1 3,5-Diphenyl-[1,2,4]thiazaphosphole 

Relevant academic research and scientific papers

Discovery of a novel, isothiazolonaphthoquinone-based small molecule activator of FOXO nuclear-cytoplasmic shuttling

FOXO factors are tumour suppressor proteins commonly inactivated in human tumours by posttranslational modifications. Furthermore, genetic variation within the FOXO3a gene is consistently associated with human longevity. Therefore, the pharmacological activation of FOXO proteins is considered as an attractive therapeutic approach to treat cancer and agerelated diseases. In order to identify agents capable of activating FOXOs, we tested a collection of small chemical compounds using image-based high content screening technology. Here, we report the discovery of LOM612 (compound 1a), a newly synthesized isothiazolonaphthoquinone as a potent FOXO relocator. Compound 1a induces nuclear translocation of a FOXO3a reporter protein as well as endogenous FOXO3a and FOXO1 in U2OS cells in a dose-dependent manner. This activity does not affect the subcellular localization of other cellular proteins including NFkB or inhibit CRM1-mediated nuclear export. Furthermore, compound 1a shows a potent antiproliferative effect in human cancer cell lines.

Synthesis and biological evaluation of novel isothiazoloquinoline quinone analogues

Natural quinones and their analogues have attracted growing attention because of their novel anticancer activities. A series of novel isothiazoloquinoline quinone analogues were synthesized and evaluated for antitumor activities against four different kind of cancer cells. Among them, isothiazoloquinolinoquinones inhibited cancer cells proliferation effectively with IC50 values in the nanomolar range, and isothiazoloquinolinoquinone 13a induced the cell apoptosis. Further exploration of possible mechanism of action indicates that 13a not only activates ROS production through NQO1-directed redox cycling but also inhibits the phosphorylation of STAT3. These findings indicate that 13a has potential use for the development of new skeleton drug candidate as an efficient substrate of NQO1 and STAT3 inhibitor.

CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF

Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.

Synthesis of spiroindene-1,3-dione isothiazolines via a cascade michael/1,3-dipolar cycloaddition reaction of 1,3,4-oxathiazol-2-one and 2-arylidene-1,3-indandiones

The reaction of 1,3,4-oxathiazol-2-one derivative with 2-arylidene-1,3-indandione to furnish novel spiroindene-1,3-dione isothiazoline derivatives by Michael/1,3-dipolar [3+2]-cycloaddition reaction was investigated. The key 1,3-dipolar cycloaddition reaction step was examined in toluene solvent at reflux temperature to obtain mixture of two regioisomers (6a and 6b – 14a and 14b) and single isomers (15–20). The scope of this new reaction was demonstrated with many examples with high reactivity and yields.

Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes

We have discovered a novel series of isothiazole-based phenylpropanoic acids as GPR120 agonists. Extensive structure-activity relationship studies led to the discovery of a potent GPR120 agonist 4x, which displayed good EC50 values in both calcium and β-arrestin assays. It also presented good pharmaceutical properties and a favorable PK profile. Moreover, it demonstrated in vivo antidiabetic activity in C57BL/6 DIO mice. Studies in WT and knockout DIO mice showed that it improved glucose handling during an OGTT via GPR120. Overall, 4x possessed promising antidiabetic effect and good safety profile to be a development candidate.

HISTONE DEACETYLASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. The condition or disorder mediated by HDAC comprises a neurodegenerative pathology. Accordingly, also provided is a method of treating a neurodegenerative pathology mediated by HDAC in a subject in need of such a treatment, comprising administering to the subject a therapeutically effective amount of at least one compound, or pharmaceutically acceptable salt thereof, described herein.

Sulfur imidations by light-induced ruthenium-catalyzed nitrene transfer reactions

N-Acyl nitrenes have been generated from a range of heterocyclic precursors, and their applications in light-induced ruthenium-catalyzed sulfur imidations have been studied. Analyzing the reaction scope and determining the structural requirements of the in situ formed electrophilic nitrogen species for effective nitrene transfer allowed a mechanistic scheme to be proposed. The mechanistic conclusions were substantiated by the identification of potential intermediates.

Optimization and Evaluation of 5-Styryl-Oxathiazol-2-one Mycobacterium tuberculosis Proteasome Inhibitors as Potential Antitubercular Agents

This is the first report of 5-styryl-oxathiazol-2-ones as inhibitors of the Mycobacterium tuberculosis (Mtb) proteasome. As part of the study, the structure-activity relationship of oxathiazolones as Mtb proteasome inhibitors has been investigated. Furthermore, the prepared compounds displayed a good selectivity profile for Mtb compared to the human proteasome. The 5-styryl-oxathiazol-2-one inhibitors identified showed little activity against replicating Mtb, but were rapidly bactericidal against nonreplicating bacteria. (E)-5-(4-Chlorostyryl)-1,3,4-oxathiazol-2-one) was most effective, reducing the colony-forming units (CFU)/mL below the detection limit in only seven days at all concentrations tested. The results suggest that this new class of Mtb proteasome inhibitors has the potential to be further developed into novel antitubercular agents for synergistic combination therapies with existing drugs.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.